Detection of a Novel Serotonin Receptor Subtype (5‐HT1E) in Human Brain: Interaction with a GTP‐Binding Protein
Authors:
- 1 August 1989
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 53 (2) , 465-471
Abstract
[3H]Serotonin (5‐hydroxytryptamine, [3H]5‐HT) was used as a radioligand probe of brain 5‐HT receptors in homogenates of human cortical tissue. Two binding sites were detected in the presence of 1 μM pindolol (to block 5‐HT1Aand 5‐HT1B receptors), and 100 nM mesulergine (to block 5‐HT1c and 5‐HT2 receptors). One of these sites demonstrated high affinity for 5‐carboxyamidotryptamine (5‐CT) and er‐gotamine, consistent with the known pharmacology of the 5‐HT1D receptor; the second site demonstrated low affinity for 5‐CT and ergotamine. Computer‐assisted analyses indicated that both drugs displayed high affinities (Ki values of 1.1 nM and 0.3 nM for 5‐CT and ergotamine, respectively) for 55% of the sites and low affinities (Ki values of 910 nM and 155 nM for 5‐CT and ergotamine, respectively) for 45% of the sites. To investigate the non‐5‐HT1D component of the binding, 100 nM 5‐CT (to block 5‐HT1A, 5TTT1B, and 5‐HT1D receptors) was coincubated with [3H]5‐HT, membranes, and mesulergine. The remaining [3H]5‐HT binding (hereafter referred to as “5‐HT1E”) displayed high affinity and saturability (KD, 5.3 nM; Bmax, 83 fmol/mg) in human cortical tissue. Competition studies with nonradioactive drugs indicated that, of the drugs tested, 5‐CT and ergotamine displayed the highest selectivity for the 5‐HT1D site versus the 5‐HT1E site. The interaction of the 5‐HT1E site with a GTP‐binding protein was demonstrated; the nonhydrolyzable derivatives of GTP, guanosine 5′‐0‐(3‐thiotriphosphate) (GTPγS) and 5′‐guanylylimidodiphosphate [Gpp(NH)p], potently inhibited binding of [3H]5‐HT to the 5‐HT1E site (IC50 values of 16 and 172 nM, respectively) while adenosine 5′‐0‐(3‐thiotriphosphate) (ATPγS) and 5′‐adenylylimidodi‐phosphate [App(NH)p] were without effect. The high affinity of 5‐HT for the site, the unique pharmacological profile of the site, and the interaction of the site with a GTP‐binding protein indicate that this site represents a unique 5‐HT receptor subtype heretofore undescribed, and which we propose to call 5‐HT1E in keeping with the current system of nomenclature in the 5‐HT receptor field.Keywords
This publication has 30 references indexed in Scilit:
- Molecular biology of 5-HT receptorsTrends in Pharmacological Sciences, 1989
- Detection and Characterization of the Serotonin 5‐HT1D Receptor in Rat and Human BrainJournal of Neurochemistry, 1988
- Identification and distribution of 5-HT3 receptors in rat brain using radioligand bindingNature, 1987
- N-Methyl derivatives of the 5-HT2 agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropaneJournal of Medicinal Chemistry, 1987
- Pharmacological Differentiation and Characterization of 5‐HT1A, 5‐HT1B, and 5‐HT1CBinding Sites in Rat Frontal CortexJournal of Neurochemistry, 1986
- Artifactual High‐Affinity and Saturable Binding of [3H]5‐Hydroxytryptamine Induced by Radioligand OxidationJournal of Neurochemistry, 1986
- Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamineNeuropharmacology, 1986
- Selective 5ht-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortexNeuropharmacology, 1984
- A practical computer-based approach to the analysis of radioligand binding experimentsComputer Programs in Biomedicine, 1983
- Discrimination of Multiple [3H]5‐Hydroxytryptamine Binding Sites by the Neuroleptic Spiperone in Rat BrainJournal of Neurochemistry, 1981